bevacizumab should no longer be marketed for breast cancer. The FDA began the process of finalizing that recommendation on December 16, 2010, the same day the European Medicines Agency said bevacizumab should still be used with paclitaxel in treating breast
Search Results
Is the Battle Over Bevacizumab Coverage Looming?
Catherine Larkin
Controversies in the Locoregional Management of Head and Neck Cancer
David M. Brizel, William Lydiatt, and A. Dimitrios Colevas
Concurrent Systemic Therapy The most common anticancer agents used concurrently with radiation in the curative treatment of squamous cell carcinoma of the head and neck (SCCHN) include cisplatin, carboplatin, paclitaxel, docetaxel, cetuximab, and 5
NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer
Thomas W. Flaig
phase III trial, which randomly assigned 542 patients whose disease had progressed on platinum-based therapy to either pembrolizumab or investigator’s choice of chemotherapy (vinflunine, paclitaxel, or docetaxel), pembrolizumab demonstrated significantly
Abstracts From the NCCN 2022 Annual Conference
Trial of Concurrent Nab-Paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer Ping Jiang, PhD 1 ; Ang Qu, PhD 1 ; Weijuan Jiang, PhD 1 ; Xiuwen Deng, PhD 1 ; Junjie Wang, PhD 1 1 Peking University Third Hospital, Beijing
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes
first-line systemic therapy. Alectinib is a preferred option if an ALK rearrangement is discovered during first-line systemic therapy (eg, carboplatin/[pemetrexed or paclitaxel]). Brigatinib, ceritinib, crizotinib, and lorlatinib are also recommended
Computed Tomography Screening for the Early Detection of Lung Cancer
Rebecca P. Petersen and David H. Harpole Jr.
. 18. Strauss GA Herndon JE Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol
Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules
Betsy L. Althaus
increasing dose intensity . Am J Clin Oncol 1999 ; 22 : 38 – 41 . 22. Livingston RB Ellis GK Gralow JR . Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
Clinical Trials: Does One Size Really Fit All?
Margaret Tempero
metastatic to liver. He asked if we had a clinical trial he could participate in. I explained that we did, but that the chemotherapy backbone of the trial was gemcitabine and albumin-bound paclitaxel. Given the BRCA1 mutation, he had a higher likelihood of
It’s About Time!
Margaret Tempero
Compared with other malignancies, the treatment landscape for pancreatic cancer is pretty sparse. The last 2 drug approvals occurred several years ago and both drugs (albumin-bound paclitaxel and liposomal irinotecan) were formulated for better
Five Patients and One Important Lesson
Margaret Tempero
FOLFIRINOX or gemcitabine and nab-paclitaxel until 2010 or later. Talk about slow progress! Most of the patients I see will die of this disease. We can prolong their lives, but it is a temporary reprieve. Invariably, when I see a new patient, he or she
